A Phase I Clinical Study Study of the Safety, Tolerability, and Pharmacokinetics of HX-1171 in Healthy Male Subjects
NCT ID: NCT01548391
Last Updated: 2012-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
66 participants
INTERVENTIONAL
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of HX15001 in Adult Healthy Volunteers.
NCT06999720
Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants
NCT05501717
Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects
NCT01475981
Clinical Trial of GX-I7 in Healthy Volunteers
NCT02860715
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects
NCT05158335
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HX-1171 20 mg (20mg 1T)
HX-1171
20mg, 200mg, 500mg
HX-1171 40 mg (20mg 2T)
HX-1171
20mg, 200mg, 500mg
HX-1171 80 mg (20mg 4T)
HX-1171
20mg, 200mg, 500mg
HX-1171 160 mg (20mg 8T)
HX-1171
20mg, 200mg, 500mg
HX-1171 300 mg (200mg 1T, 20mg 5T)
HX-1171
20mg, 200mg, 500mg
HX-1171 600 mg (200mg 3T)
HX-1171
20mg, 200mg, 500mg
HX-1171 1200 mg (500mg 2T, 200mg 1T)
HX-1171
20mg, 200mg, 500mg
HX-1171 1500 mg (500mg 3T)
HX-1171
20mg, 200mg, 500mg
HX-1171 2000 mg (500mg 4T)
HX-1171
20mg, 200mg, 500mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HX-1171
20mg, 200mg, 500mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be able to comply with the requirement of the study. Subject must provide written informed consent prior to study participation.
Exclusion Criteria
* History of known hypersensitivity to drugs including HX-1171.
20 Years
40 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biotoxtech Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asan Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Research Center, Asan Medical Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-0070
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.